Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II tepotinib study in advanced MET-altered non-small cell lung cancer
NL-OMON58630Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Started Mar 2019; status: completed.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON58630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58630.